[Form 3] ACHIEVE LIFE SCIENCES, INC. Initial Statement of Beneficial Ownership
Craig Donnelly, Chief Operations Officer of Achieve Life Sciences (ACHV), filed an initial Form 3 reporting direct ownership of 52,372 shares of common stock and two stock option awards. One option covers 25,000 shares exercisable beginning 03/14/2033 at $4.53; the other covers 22,500 shares exercisable beginning 01/22/2034 at $4.55. Vesting schedules for each grant are disclosed in the filing.
Craig Donnelly, Chief Operations Officer di Achieve Life Sciences (ACHV), ha depositato un modulo iniziale Form 3 comunicando la proprietà diretta di 52.372 azioni ordinarie e due premi di stock option. Una opzione copre 25.000 azioni exercisable a partire dal 14/03/2033 al prezzo di $4,53; l'altra copre 22.500 azioni exercisable a partire dal 22/01/2034 al prezzo di $4,55. I piani di vesting per ciascun premio sono indicati nel filing.
Craig Donnelly, Director de Operaciones de Achieve Life Sciences (ACHV), presentó un Formulario 3 inicial informando la propiedad directa de 52.372 acciones comunes y dos premios de opciones sobre acciones. Una opción cubre 25.000 acciones ejercibles a partir del 14/03/2033 a $4,53; la otra cubre 22.500 acciones ejercibles a partir del 22/01/2034 a $4,55. Los calendarios de vesting para cada adjudicación se divulgan en la presentación.
Craig Donnelly는 Achieve Life Sciences(ACHV)의 최고운영책임자(COO)로서 최초 Form 3를 제출하여 52,372주의 보통주 직접 소유와 두 건의 스톡 옵션 보상을 보고했습니다. 한 옵션은 25,000주를 포함하며 2033년 3월 14일에 행사 가능하고 가격은 $4.53입니다; 다른 하나는 22,500주를 포함하며 2034년 1월 22일에 행사 가능하고 가격은 $4.55입니다. 각 보상의 베스팅 일정은 신고서에 기재되어 있습니다.
Craig Donnelly, directeur des opérations d'Achieve Life Sciences (ACHV), a déposé une première Form 3 annonçant la propriété directe de 52.372 actions ordinaires et deux lots d'options d'achat d'actions. Une option couvre 25.000 actions exercables à partir du 14/03/2033 à $4,53; l'autre couvre 22.500 actions exercables à partir du 22/01/2034 à $4,55. Les calendriers de vesting pour chaque attribution sont divulgués dans le dossier.
Craig Donnelly, Chief Operations Officer von Achieve Life Sciences (ACHV), hat ein erstes Form 3 eingereicht und direkte Eigentumsverhältnisse an 52.372 Stammaktien sowie zwei Aktienoptionszusagen gemeldet. Eine Option umfasst 25.000 Aktien, die ab dem 14.03.2033 zu einem Ausübungspreis von $4,53 exercisable sind; die andere umfasst 22.500 Aktien, die ab dem 22.01.2034 zu $4,55 exercisable sind. Vesting-Pläne für jede Zuteilung werden in der Einreichung offengelegt.
Craig Donnelly، مدير العمليات في Achieve Life Sciences (ACHV)، قد قدم نموذج Form 3 ابتدائي للإبلاغ عن ملكية مباشرة لـ 52,372 سهم من الأسهم العادية واثنين من جوائز خيارات الأسهم. تغطي إحدى الخيارات 25,000 سهمًا يمكن ممارستها اعتبارًا من 14/03/2033 بسعر $4.53؛ أما الأخرى فتمتد لتغطي 22,500 سهمًا يمكن ممارستها اعتبارًا من 22/01/2034 بسعر $4.55. جداول الاستحقاق لكل من المنحتين مذكورة في الملف.
Craig Donnelly,Achieve Life Sciences(ACHV)首席运营官,提交了初始 Form 3,报告直接持有 52,372 股普通股以及两项股票期权奖励。一项期权覆盖 25,000 股,将于 2033-03-14 起行权,行权价为 $4.53;另一项覆盖 22,500 股,将于 2034-01-22 起行权,行权价为 $4.55。每项授予的归属时间表在申报中披露。
- Initial Section 16 disclosure filed for an officer, improving transparency
- Detailed vesting schedules and exercise prices for both option grants were provided
- None.
Insights
TL;DR: Officer disclosed modest direct holdings and standard employee option grants; no immediate dilutive impact.
The Form 3 reports direct ownership of 52,372 shares and two option grants totaling 47,500 shares with exercise prices near $4.53–$4.55 and multi-year vesting. This is a routine Section 16 initial disclosure that provides transparency on insider holdings and potential future dilution as options vest and become exercisable. No cash, debt, or revenue figures are included.
TL;DR: Filing meets Section 16 disclosure requirements and details vesting mechanics for governance oversight.
The submission documents the reporting officer's beneficial ownership and the vesting schedule for two option awards, allowing stakeholders to track insider incentives and timing of potential exercises. The signature is by attorney-in-fact, consistent with procedural practice. No governance issues or departures are reported.
Craig Donnelly, Chief Operations Officer di Achieve Life Sciences (ACHV), ha depositato un modulo iniziale Form 3 comunicando la proprietà diretta di 52.372 azioni ordinarie e due premi di stock option. Una opzione copre 25.000 azioni exercisable a partire dal 14/03/2033 al prezzo di $4,53; l'altra copre 22.500 azioni exercisable a partire dal 22/01/2034 al prezzo di $4,55. I piani di vesting per ciascun premio sono indicati nel filing.
Craig Donnelly, Director de Operaciones de Achieve Life Sciences (ACHV), presentó un Formulario 3 inicial informando la propiedad directa de 52.372 acciones comunes y dos premios de opciones sobre acciones. Una opción cubre 25.000 acciones ejercibles a partir del 14/03/2033 a $4,53; la otra cubre 22.500 acciones ejercibles a partir del 22/01/2034 a $4,55. Los calendarios de vesting para cada adjudicación se divulgan en la presentación.
Craig Donnelly는 Achieve Life Sciences(ACHV)의 최고운영책임자(COO)로서 최초 Form 3를 제출하여 52,372주의 보통주 직접 소유와 두 건의 스톡 옵션 보상을 보고했습니다. 한 옵션은 25,000주를 포함하며 2033년 3월 14일에 행사 가능하고 가격은 $4.53입니다; 다른 하나는 22,500주를 포함하며 2034년 1월 22일에 행사 가능하고 가격은 $4.55입니다. 각 보상의 베스팅 일정은 신고서에 기재되어 있습니다.
Craig Donnelly, directeur des opérations d'Achieve Life Sciences (ACHV), a déposé une première Form 3 annonçant la propriété directe de 52.372 actions ordinaires et deux lots d'options d'achat d'actions. Une option couvre 25.000 actions exercables à partir du 14/03/2033 à $4,53; l'autre couvre 22.500 actions exercables à partir du 22/01/2034 à $4,55. Les calendriers de vesting pour chaque attribution sont divulgués dans le dossier.
Craig Donnelly, Chief Operations Officer von Achieve Life Sciences (ACHV), hat ein erstes Form 3 eingereicht und direkte Eigentumsverhältnisse an 52.372 Stammaktien sowie zwei Aktienoptionszusagen gemeldet. Eine Option umfasst 25.000 Aktien, die ab dem 14.03.2033 zu einem Ausübungspreis von $4,53 exercisable sind; die andere umfasst 22.500 Aktien, die ab dem 22.01.2034 zu $4,55 exercisable sind. Vesting-Pläne für jede Zuteilung werden in der Einreichung offengelegt.